Quarterly ResultMay 6, 2026, 04:18 PM
Context Therapeutics Q1 Net Loss $(8.68)M; Cash $54.5M
AI Summary
Context Therapeutics Inc. reported a net loss of $(8.68) million for the first quarter of 2026, a significant increase from $(4.58) million in the same period last year. The company's cash and cash equivalents decreased to $54.5 million as of March 31, 2026, with cash used in operating activities totaling $(11.43) million for the quarter. Research and development expenses more than doubled to $7.02 million as the company advances its clinical-stage product candidates, contributing to an accumulated deficit of $139.6 million.
Key Highlights
- Net loss for Q1 2026 was $(8.68) million, compared to $(4.58) million in Q1 2025.
- Cash and cash equivalents decreased to $54.5 million as of March 31, 2026.
- Research and development expenses rose to $7.02 million in Q1 2026 from $3.46 million in Q1 2025.
- Cash used in operating activities was $(11.43) million for Q1 2026.
- Accumulated deficit reached $139.6 million as of March 31, 2026.
- Company expects current cash to fund operations for at least 12 months.
- Authorized common stock increased to 200,000,000 shares in September 2024.
- Total outstanding warrants to acquire common stock were 9,164,541 at March 31, 2026.